Abzena Supplies Clinical Trial Material for Angiex's Phase I Cancer Study

12 August 2024

Angiex’s Phase I Cancer Study Bolstered by Abzena’s Clinical Trial Support

Angiex has advanced its Phase I cancer study with essential clinical trial materials provided by Abzena, a global leader in biopharmaceutical development and manufacturing. This collaboration supports the development of Angiex’s AGX101, a TM4SF1-targeted antibody-drug conjugate (ADC) designed to treat aggressive cancers by focusing on tumor blood vessels. The Phase I trial is a crucial step in evaluating the safety and potential efficacy of this innovative therapy.

Pharmaceutical Outsourcing covered this milestone, emphasizing the significance of Abzena’s role in enabling Angiex to move forward with its clinical trial. As a trusted source for pharmaceutical outsourcing and development news, Pharmaceutical Outsourcing provides insight into the strategic partnerships that are essential for bringing groundbreaking therapies like AGX101 to patients. Their coverage highlights the critical impact of CDMOs like Abzena in advancing drug development.

About Angiex

Angiex, Inc. is a privately held biotech whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by leading scientific experts in angiogenesis, vascular biology, and oncology. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus of cells in the tumor environment. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. Angiex’s lead product, AGX101, with its novel and differentiated mechanisms of action, represents a first-in-class drug with potential to address high unmet medical needs.

Get in touch